Intellia Therapeutics (NTLA) Tops Q2 EPS by 5c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.98), $0.05 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $11.99 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) In Lead To Buy Ultra Maritime For ~$3.5B - FT
• Navient discloses ransomware breach at third-party law firm
• FBI investigates Alarum unit over alleged co-opted home devices - Bloomberg